Click here to close now.

SYS-CON MEDIA Authors: Jayaram Krishnaswamy, Robin Kent, Pat Romanski, Jason Bloomberg, Lori MacVittie

News Feed Item

Antibacterial Drugs: World Industry and Market Prospects 2014-2024

LONDON, March 11, 2014 /PRNewswire/ --

Antibacterials - new analysis showing business trends, R&D, and revenue forecasts

What is the future of medicines treating bacterial infections? For those drugs you get new sales predictions, also exploring research and development. Those treatments hold high potentials. There you assess results, progress, therapies, and opportunities.

Knowledge facilitates success. Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. There you stay ahead in data on microbial diseases, finding commercial prospects to benefit your influence.

Read on to explore antibiotics for human healthcare, seeing how high sales can go.

Forecasts to 2024 and other analyses explain and predict that antimicrobials market

Why miss data you need? Why struggle to find it, or fall behind? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find recent results, growth rates, market shares, and discussions.

Also you see the potential of research and development. That study gives 126 tables, 102 charts, and interviews with three companies.

There you assess the future of antibacterials, hearing how patients, doctors, and pharma companies can benefit. You stay ahead, then, finding where money lies, assessing the most lucrative selling prospects.

And the following sections show how that new investigation helps your research, analyses and decisions. See there how you could benefit your authority and save time, staying ahead.

Sales predictions for the world antibiotics market and submarkets

What is that biomedical industry's potential? What are the secrets of its progress? Discover in our report overall world revenue to 2024 for those bacteria-treating agents.

Also find individual revenue predictions to 2024 for six therapeutic submarkets at world level:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other treatments for bacterial infections.

There you explore prospects from 2014, hearing where you could profit from novel agents and generic drugs (generics). Investigate competition, developments, and rising sales.

That study also predicts and discusses leading medicines' sales potentials

To see an exec summary of this report please email Sara Peerun on [email protected] .

Revenue predictions for leading and expected products

How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 43 products - marketed agents and drugs awaiting launch.

You assess top products, including these:
• Zyvox
• Augmentin
• Cubicin
• Generic amoxicillin
• Avelox.

There you find medicines and years with highest predicted sales. Also you examine competitors and get an understanding of recent challenges, trends, and outlooks.

For that overall market, the report also shows geographical revenue predictions.

National markets - what are the demands for antibacterial therapies?

In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2014 to 2024. See where and how.

Our analyses show you individual revenue forecasts to 2024 for a regional block and 12 national markets:
United States (US)
• European Union (EU) - also with separate forecasts for France, Germany, the UK, Italy, and Spain (EU5 countries)
Japan
South Korea
• The BRIC nations - Brazil, Russia, India, and China.

For healing people and saving lives, you explore progress, needs and potentials. Find how pharma companies can satisfy those demands for fighting bacterial infections, also assessing the expected financial gains.

And what events change that industry? Our work shows you, discussing trends, challenges and opportunities.

Market forces and issues - what affects antibiotic developers, producers and sellers?

The report shows you issues and events affecting that industry and market from 2014, including these:
• Antibacterial drug consumption statistics at national level
• Incidences of urinary tract, skin, and respiratory tract infections from bacteria
• Generic competition for leading brands - effects of patent expiries
• Prescription control to reduce bacterial resistance, including that of methicillin-resistant S. aureus (MRSA)
• Encouraging antibiotic drug discovery and development - push and pull incentives, inc. public-private collaborations.

And you explore these influences, among others:
• R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations
• Oxazolidinones and other new drug classes to stimulate the market
• Treating and preventing hospital-acquired infections (HAIs)
• Potential for smaller pharma companies to succeed, esp. with partnerships
• Guidelines from regulatory bodies and other healthcare policies.

Discover what the future holds. There you explore political, economic, social, and technological questions. See, too, how R&D lets companies benefit patients.

There you find what stimulates and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on [email protected]

Analysis of top companies and potential for market growth - what revenue is possible?

From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from bacteria-treating drugs.

So what happens next? Our study predicts that world market will reach $42.75bn in 2018, with further expansion to 2024.

That work also explores activities and potentials of these companies, among others:
• Pfizer
• GlaxoSmithKline (GSK)
• Novartis
• Merck & Co.
• Bayer
• Cubist Pharmaceuticals
• Daiichi Sankyo.

R&D in that industry holds strengths, and from 2014 opportunity arises. Patients, payers, and companies will benefit. Discover what is possible.

And you will be able to see how that market can perform, staying ahead in knowledge and benefiting your reputation for commercial insight.

Ways Antibacterial Drugs: World Industry and Market Prospects 2014-2024  helps you

In particular, that new investigation gives you this information:
• Revenues there to 2024 at world level, for 6 submarkets, and 43 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.

Knowledge found nowhere else, helping your searches, analyses, and planning

Our study gives independent data. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.

With that original research and analysis you are less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort. And also help your plans, decisions, influence, and competing.

The new report shows commercial potentials of medicines for human infective diseases. There you explore trends and R&D, and investigate future sales. So avoid missing out - please order now.

Companies Listed in this report:
Abbott
AbbVie
Achaogen
ACS Dobfar
Actavis
Actelion Pharmaceuticals
Aeras
Affinium Pharmaceuticals
Alcon
Alkem Laboratories
Allied Pharma
AmpliPhi Bioscience
Apotex
APP Pharmaceuticals
Aptalis Pharma
Aquapharm Biodiscovery
Aradigm
Aridis Pharmaceuticals
Arsanis Biosciences
Ascend Therapeutics
Aspen
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals
Basilea Pharmaceutica
Bayer
Biomax Biotechnics
Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority (BARDA)
Brazilian National Health Surveillance Agency
Cadila Healthcare
Calixa Therapeutics
Cardeas Pharma
Cellceutix
Cempra Pharmaceuticals
Centers for Disease Control and Prevention (CDC)
Chinese Ministry of Health
Chiron
Cipla
Claris Lifesciences
Clinigen
Cornerstone Therapeutics
Corona Remedies
Critical Therapeutics
Cubist Pharmaceuticals
Curetis
Daiichi Sankyo
Dainippon Sumitomo
Destiny Pharma
Discuva
Dr. Reddy's Laboratories
Duke University
Durata Therapeutics
Eli Lilly
Emcure Pharmaceuticals
Eros Pharma
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Fitch Ratings Agency
Food and Drug Administration (US FDA)
Forest Laboratories
Fraunhofer-Gesellschaft
Furiex Pharmaceuticals
Gate Pharma
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark Generics
GlycoVaxyn
Guangdong BeiKang
Hetero
Hi Tech Pharma
Hikma Pharmaceuticals
Hospira
Indian Ministry of Health and Family Welfare
Insmed
Intercell
Itochu Chemical Frontier
Janssen Pharmaceutica
Japanese Ministry of Health Labor and Welfare
Johns Hopkins University School of Medicine
Johnson & Johnson
KaloBios
Kenta Biotech
Kuhnil Pharm
Lupin
Macleod Pharmaceuticals
Medicines and Healthcare Products Regulatory Agency
Medicis
MedImmune
Medison Pharma
Medsintez
Meiji Seika Pharma
Melinta Therapeutics
Merck & Co.
MerLion Pharmaceuticals
Microlabs
MicuRx Pharmaceuticals
Ministry of Health, Labour and Welfare (MHLW, Japan)
Mpex Pharmaceuticals
Mylan
Nabriva Therapeutics
Nalneva
National Institute for Health and Clinical Excellence
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Neiss Labs
Nektar Therapeutics
Nichi-Iko Pharmaceuticals
Nipro Pharma
Novacta Biosystems
Novartis
Novexel
Optimer Pharmaceuticals
Orchid Healthcare
Paratek Pharmaceuticals
Pearl Therapeutics
Pfizer
Phico Therapeutics
Piramal Healthcare,
Plenus Pharmaceuticals
Pliva
Polyphor
Procarta Biosystems
Procter & Gamble
Ranbaxy Labs
Redx Pharma
Roche
Roxane
R-Pharma
RQx Pharmaceutical
Sagent Pharmaceuticals
Sandoz
Sanofi
Sanofi Pasteur
Savara Pharmaceuticals
Sawai Pharmaceutical
Sequella
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Shionogi
Shire
Sidmak Labs
Sistema Nacional de Gerenciamento de Produtos Controlados
Solitaire Pharmacia
Specialised Therapeutics
Sunovion Pharma
TaiGen Biotechnology
Taisho Pharmaceuticals
Taiyo Yakuhin
Takeda
TAP Holdings
Targanta Therapeutics
Tedec-Meiji Farma
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Torrent Pharmaceuticals
Trius Therapeutics
TTY Biopharma
Unichem Laboratories
University of Leicester
University of Michigan
US Department of Health
Valeant Pharmaceuticals
Vansen Pharma
Vicuron
ViroPharma
Warner Chilcott
Watson
Wockhardt
World Health Organization (WHO)
Zhejiang Medicine Company
Zuelig Pharma
Zydus Pharmaceuticals

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel : +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1215/Antibacterial-Drugs-World-Industry-and-Market-Prospects-2014-2024


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists will discuss how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations m...
Public Cloud IaaS started it's life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small and medium sized business have server closets and colocation footprints filled with servers and storage gear. While on-premise environment virtualization may have peaked at 75%, the Public Cloud has lagged in ado...
So I guess we’ve officially entered a new era of lean and mean. I say this with the announcement of Ubuntu Snappy Core, “designed for lightweight cloud container hosts running Docker and for smart devices,” according to Canonical. “Snappy Ubuntu Core is the smallest Ubuntu available, designed for security and efficiency in devices or on the cloud.” This first version of Snappy Ubuntu Core features secure app containment and Docker 1.6 (1.5 in main release), is available on public clouds, ...
ProfitBricks, the provider of painless cloud infrastructure for IaaS, today announced the release of a Node.js SDK written against its recently launched REST API. This new JavaScript based library provides coverage for all existing ProfitBricks REST API functions. With additional libraries set to release this month, ProfitBricks continues to prove its dedication to the DevOps community and commitment to making cloud migrations and cloud management painless. Node.js is an open source, cross-pl...
In this session we look at creating interactive communications via the web by adding messaging, file transfer, and group communication (group chat and audio/video conferencing) into the web experience. We will also discuss potential applications of this technology in areas including B2B, B2C, P2P, and gaming. Peter is Technical Director at Acision. He graduated from The University of Edinburgh in 2000 with a BSc (Hons) in Computer Science. After graduation Peter worked on a PSTN switch dev...
Many of the well-known examples of DevOps success we read in blogs on the Internet paint an idyllic picture of DevOps productivity. A team was facing a stodgy, slow-moving operations department, teams weren’t delivering software on time. Those teams moved to DevOps, became proactive about infrastructure and deployment automation, and an overnight transition to productivity ensues. People are promoted, projects are successful, and developers and system administrators dance hand-in-hand in a final...
SYS-CON Events announced today the IoT Bootcamp – Jumpstart Your IoT Strategy, being held June 9–10, 2015, in conjunction with 16th Cloud Expo and Internet of @ThingsExpo at the Javits Center in New York City. This is your chance to jumpstart your IoT strategy. Combined with real-world scenarios and use cases, the IoT Bootcamp is not just based on presentations but includes hands-on demos and walkthroughs. We will introduce you to a variety of Do-It-Yourself IoT platforms including Arduino, Ras...
Health care systems across the globe are under enormous strain, as facilities reach capacity and costs continue to rise. M2M and the Internet of Things have the potential to transform the industry through connected health solutions that can make care more efficient while reducing costs. In fact, Vodafone's annual M2M Barometer Report forecasts M2M applications rising to 57 percent in health care and life sciences by 2016. Lively is one of Vodafone's health care partners, whose solutions enable o...
SYS-CON Events announced today that Vicom Computer Services, Inc., a provider of technology and service solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. They are located at booth #427. Vicom Computer Services, Inc. is a progressive leader in the technology industry for over 30 years. Headquartered in the NY Metropolitan area. Vicom provides products and services based on today’s requirements...
SYS-CON Events announced today the DevOps Foundation Certification Course, being held June ?, 2015, in conjunction with DevOps Summit and 16th Cloud Expo at the Javits Center in New York City, NY. This sixteen (16) hour course provides an introduction to DevOps – the cultural and professional movement that stresses communication, collaboration, integration and automation in order to improve the flow of work between software developers and IT operations professionals. Improved workflows will res...
Dave will share his insights on how Internet of Things for Enterprises are transforming and making more productive and efficient operations and maintenance (O&M) procedures in the cleantech industry and beyond. Speaker Bio: Dave Landa is chief operating officer of Cybozu Corp (kintone US). Based in the San Francisco Bay Area, Dave has been on the forefront of the Cloud revolution driving strategic business development on the executive teams of multiple leading Software as a Services (SaaS) ap...
SOASTA, the leader in performance analytics, today reported record growth of the CloudTest community, exceeding 30,000 registered users of the CloudTest platform in Q1 2015. SOASTA also announced widespread adoption of its Web and mobile testing solutions, with more than 1,600 customers completing more than 285,000 tests using CloudTest during the quarter. This rapid growth shows that DevOps-driven digital businesses are embracing a more continuous approach to testing, and CloudTest is meeting t...
Recent technology advances in miniaturization has positioned the wearables as the pinnacle of technology convergence with the human body. We inquire if wearables are mere standard miniaturized devices extended with the connectivity and present our views on considerations like design, applications, performance, efficiency, interoperability, usage scenarios, human device interaction and consequent trade-offs enabling wearables to impart optimal value.
SYS-CON Media announced today that John Treadway’s blog has exceeded 475,000 page views. John Treadway, Vice President at Cloud Technology Partners, has surpassed 475,000 page views on the SYS-CON family of online magazines, which includes Cloud Computing Journal, Internet of Things Journal, Big Data Journal, Microservices Journal, and several others. His blog home page at SYS-CON can be found at JohnTreadway.SYS-CON.com.
“In the past year we've seen a lot of stabilization of WebRTC. You can now use it in production with a far greater degree of certainty. A lot of the real developments in the past year have been in things like the data channel, which will enable a whole new type of application," explained Peter Dunkley, Technical Director at Acision, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.